A Pilot Study on the Effect of Cannabis Oil in Untreatable Liver Cancer Patients
to study the anti-tumor effect of cannabis oil (THC10% / CBD5%) in untreatable HCC patients based on mRECIST and RECIST criteria
Hepatocellular Carcinoma|Cannabis
DRUG: Medical Cannabis
Tumor size, Tumor size based on RECIST and mRECIST criteria, 9 months
Tumor size, Tumor size based on RECIST and mRECIST criteria, 3 months|Tumor size, Tumor size based on RECIST and mRECIST criteria, 6 months|Tumor markers, Alfa-foetoprotein (AFP) and des-gamma-carboxy-protrombine (DGCPT), 3 months|Tumor markers, Alfa-foetoprotein (AFP) and des-gamma-carboxy-protrombine (DGCPT), 6 months|Tumor markers, Alfa-foetoprotein (AFP) and des-gamma-carboxy-protrombine (DGCPT), 9 months|Quality of Life questionnaires, EORTC-QLQ30 and -HCC18, 3 months|Quality of Life questionnaires, EORTC-QLQ30 and -HCC18, 6 months|Quality of Life questionnaires, EORTC-QLQ30 and -HCC18, 9 months
to study the anti-tumor effect of cannabis oil (THC10% / CBD5%) in untreatable HCC patients based on mRECIST and RECIST criteria